These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 21417957)

  • 41. Management of dyslipidemia in the high-risk patient.
    Stein EA
    Am Heart J; 2002 Dec; 144(6 Suppl):S43-50. PubMed ID: 12486415
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Statin drug interactions and related adverse reactions.
    Bellosta S; Corsini A
    Expert Opin Drug Saf; 2012 Nov; 11(6):933-46. PubMed ID: 22866966
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ezetimibe plus fenofibrate: a new combination therapy for the management of mixed hyperlipidaemia?
    Farnier M
    Expert Opin Pharmacother; 2007 Jun; 8(9):1345-52. PubMed ID: 17563268
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events.
    Taher TH; Dzavik V; Reteff EM; Pearson GJ; Woloschuk BL; Francis GA
    Am J Cardiol; 2002 Feb; 89(4):390-4. PubMed ID: 11835917
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Simvastatin interactions with other drugs.
    Florentin M; Elisaf MS
    Expert Opin Drug Saf; 2012 May; 11(3):439-44. PubMed ID: 22416996
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combination of fenofibrate with non-statin drug regimens.
    Agouridis AP; Filippatos TD; Derdemezis CS; Mikhailidis DP; Elisaf MS
    Curr Pharm Des; 2010 Oct; 16(30):3401-16. PubMed ID: 20819059
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fixed-dose combination therapy with statins: strengths, limitations, and clinical and regulatory considerations.
    Hennekens CH
    Am J Cardiovasc Drugs; 2008; 8(3):155-60. PubMed ID: 18533736
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Statin-fibrate combination: therapy for hyperlipidemia: a review.
    Wierzbicki AS; Mikhailidis DP; Wray R; Schacter M; Cramb R; Simpson WG; Byrne CB
    Curr Med Res Opin; 2003; 19(3):155-68. PubMed ID: 12814127
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Myopathy induced by statin-ezetimibe combination: Evaluation of potential risk factors.
    Brahmachari B; Chatterjee S
    Indian J Pharmacol; 2015; 47(5):563-4. PubMed ID: 26600650
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fenofibric acid for hyperlipidemia.
    Saurav A; Kaushik M; Mohiuddin SM
    Expert Opin Pharmacother; 2012 Apr; 13(5):717-22. PubMed ID: 22404421
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety considerations for statins.
    Bolego C; Baetta R; Bellosta S; Corsini A; Paoletti R
    Curr Opin Lipidol; 2002 Dec; 13(6):637-44. PubMed ID: 12441888
    [TBL] [Abstract][Full Text] [Related]  

  • 52. ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials.
    Ruscica M; Banach M; Sahebkar A; Corsini A; Sirtori CR
    Expert Opin Pharmacother; 2019 May; 20(7):791-803. PubMed ID: 30810432
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effective use of combination lipid therapy.
    Vasudevan AR; Jones PH
    Curr Atheroscler Rep; 2006 Jan; 8(1):76-84. PubMed ID: 16455018
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Statin intolerance: now a solved problem.
    Sikka P; Kapoor S; Bindra VK; Sharma M; Vishwakarma P; Saxena KK
    J Postgrad Med; 2011; 57(4):321-8. PubMed ID: 22120862
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Meta-analysis of safety of the coadministration of statin with fenofibrate in patients with combined hyperlipidemia.
    Guo J; Meng F; Ma N; Li C; Ding Z; Wang H; Hou R; Qin Y
    Am J Cardiol; 2012 Nov; 110(9):1296-301. PubMed ID: 22840347
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A safety look at currently available statins.
    Moghadasian MH
    Expert Opin Drug Saf; 2002 Sep; 1(3):269-74. PubMed ID: 12904142
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term statin safety and efficacy in secondary prevention: can combination therapy improve outcomes?
    Wascher TC
    Atheroscler Suppl; 2003 Dec; 4(5):11-6. PubMed ID: 14980230
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Fibrate and statine myopathy].
    Finsterer J
    Nervenarzt; 2003 Feb; 74(2):115-22. PubMed ID: 12596012
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Statin Intolerance: the Clinician's Perspective.
    Stulc T; Ceška R; Gotto AM
    Curr Atheroscler Rep; 2015 Dec; 17(12):69. PubMed ID: 26490078
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The controversy of a wider statin utilization: why?
    Mansi I; Mortensen E
    Expert Opin Drug Saf; 2013 May; 12(3):327-37. PubMed ID: 23488561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.